Evidence map›Paper›PMID 38226207›Full record

ReviewHeliyon2024

Overview of processed excipients in ocular drug delivery: Opportunities so far and bottlenecks.

Sumel Ashique, Neeraj Mishra, Sourav Mohanto, B H Jaswanth Gowda, Shubneesh Kumar, Amisha S Raikar, Priya Masand, Ashish Garg, Priyanka Goswami, Ivan Kahwa

RetractedOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 30 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
4 · The record

Corrections and comments

  • Retraction · 2026-03-30Author Unresponsive · Concerns/Issues about Referencing/Attributions · Error in Text · Investigation by Journal/Publisher · Unreliable Results and/or Conclusions ·
5 · Who and what money

Authors and funding

10 authors at 5 institutions in 3 countries.

Sumel AshiqueDepartment of Pharmaceutical Sciences, Bengal College of Pharmaceutical Sciences & Research, Durgapur 713212, West Bengal, India.
Neeraj MishraAmity Institute of Pharmacy, Amity University Madhya Pradesh, Gwalior, 474005, India.
Sourav MohantoDepartment of Pharmaceutics, Yenepoya Pharmacy College & Research Centre, Yenepoya (Deemed to Be University), Mangalore, 575018, India.
B H Jaswanth GowdaSchool of Pharmacy, Queen's University Belfast, Medical Biology Centre, Belfast BT9 7BL, UK.
Shubneesh KumarDepartment of Pharmaceutics, Bharat Institute of Technology, School of Pharmacy, Meerut 250103, UP, India.
Amisha S RaikarDepartment of Pharmaceutics, PES Rajaram and Tarabai Bandekar College of Pharmacy, Ponda, Goa 403401, India.
Priya MasandDepartment of Pharmaceutical Technology, Meerut Institute of Engineering & Technology, (MIET), NH-58, Delhi-Roorkee Highway, Meerut, Uttar Pradesh 250005, India.
Ashish GargDepartment of Pharmaceutics, Guru Ramdas Khalsa Institute of Science and Technology (Pharmacy), Jabalpur, Madhya Pradesh, India.
Priyanka GoswamiDepartment of Pharmacognosy, Saraswati Institute of Pharmaceutical Sciences, Gandhinagar 382355, Gujarat, India.
Ivan KahwaDepartment of Pharmacy, Faculty of Medicine, Mbarara University of Science and Technology, P.O Box 1410, Mbarara, Uganda.
Indian Education Society's V. N. Sule Guruji English Medium School · INMbarara University of Science and Technology · UGQueen's University Belfast · GBShobhit University · INYenepoya University · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ocular drug delivery presents a unique set of challenges owing to the complex anatomy and physiology of the eye. Processed excipients have emerged as crucial components in overcoming these challenges and improving the efficacy and safety of ocular drug delivery systems. This comprehensive overview examines the opportunities that processed excipients offer in enhancing drug delivery to the eye. By analyzing the current landscape, this review highlights the successful applications of processed excipients, such as micro- and nano-formulations, sustained-release systems, and targeted delivery strategies. Furthermore, this article delves into the bottlenecks that have impeded the widespread adoption of these excipients, including formulation stability, biocompatibility, regulatory constraints, and cost-effectiveness. Through a critical evaluation of existing research and industry practices, this review aims to provide insights into the potential avenues for innovation and development in ocular drug delivery, with a focus on addressing the existing challenges associated with processed excipients. This synthesis contributes to a deeper understanding of the promising role of processed excipients in improving ocular drug delivery systems and encourages further research and development in this rapidly evolving field.

Indexed as

Drug deliveryExcipientEyeFormulationNanoparticlesOcularPolymers

Identifiers

PMID38226207
PMCPMC10788286
OpenAlexW4390124467

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.